Clinical trials: Neoplasms, Germ Cell and Embryonal
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Ependymoma, High Grade Gliomas
Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma
Pediatric patients 6-21 years of age with supratentorial recurrent, refractory, or progressive pediatric ependymoma and high-grade glioma (HGG) will be included in this study of treatment with Rhenium-186 Nanoliposome (186RNL).
- Trial name
- NCT07061626
- Testing
- Rhenium-186 Nanoliposome
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Cerenome
Advanced Malignancy, Advanced Solid Tumors
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
Phase 1b/2a, open-label, sequential dose escalation and expansion study of AMG 232 in combination with trametinib and dabrafenib in subjects with metastatic melanoma followed by a direct comparison of AMG 232 combined with…
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology
- Trial name
- NCT02110355
- Testing
- AMG 232, Trametinib, Dabrafenib
- Where
- 7 sites in United States, Australia
- Volunteers
- 31 people
- Sponsor
- Kartos Therapeutics, Inc.
High Grade Glioma, Glioblastoma Multiforme
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
This is a study of DSP-0390 in patients with recurrent high grade glioma.
- Trial name
- NCT05023551
- Testing
- DSP-0390
- Where
- 9 sites in United States, Japan
- Volunteers
- 39 people
- Sponsor
- Sumitomo Pharma America, Inc.
Melanoma (Skin)
Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma
This clinical study is designed as a randomized, double-blind trial. Subjects with unresectable, metastatic, or recurrent skin melanoma will be randomized to one of the two study groups (BCD-201 group and Keytruda group) at a 1:1…
- Trial name
- NCT05986331
- Testing
- BCD-201, Keytruda
- Where
- 3 sites in Russia
- Volunteers
- 366 people
- Sponsor
- Biocad
Melanoma
Abraxane and Temodar Plus Genasense in Advanced Melanoma
This study is designed to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of combination treatment with Temodar®, Genasense®, and Abraxane® in chemotherapy-naïve subjects with advanced melanoma and normal…
- Trial name
- NCT00409383
- Testing
- Genasense® (oblimersen), Abraxane® (paclitaxel protein-bound particles for injectable suspension), Temodar® (temozolomide)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Genta Incorporated
Neuroendocrine Tumors
Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study
Subjects achieving a clinical response in study OX4218s with a biomarker reduction or symptom response are eligible to enroll in this rollover study to continue once every three weeks fosbretabulin infusions for up to one year.
- Trial name
- NCT02279602
- Testing
- fosbretabulin
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Mateon Therapeutics
Malignant Glioma, Recurrent Ependymoma
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
This study will evaluate the administration of AdV-tk followed by valacyclovir in children with malignant glioma, including glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), as well as recurrent ependymomas in…
- Trial name
- NCT00634231
- Testing
- AdV-tk, valacyclovir, Radiation
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Candel Therapeutics, Inc.
Neoplasm Metastasis
Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors
The CC-90003-ST -001 trial is a first-in-man, open-label study in subjects with locally-advanced or wide spread cancers to determine if CC-90003 (an oral medication) can be adequately tolerated with minimal side effects.
- Trial name
- NCT02313012
- Testing
- CC-90003
- Where
- 5 sites in United States, Australia
- Volunteers
- 19 people
- Sponsor
- Celgene
Malignant Melanoma, Melanoma (Skin)
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
The purpose of this study is to find out if two new treatment cancer vaccines called SCIB1 and iSCIB1+ can be used safely when added to nivolumab (Opdivo) with ipilimumab (Yervoy), or SCIB1 with pembrolizumab (Keytruda).
- Conditions
- Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV
- Trial name
- NCT04079166
- Testing
- SCIB1 or iSCIB1+ DNA vaccine
- Where
- 15 sites in United Kingdom
- Volunteers
- 173 people
- Sponsor
- Scancell Ltd
Relapsed or Refractory Neuroblastoma
Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children
This single-arm, multicenter clinical study will treat the patient who have relapsed or refractory neuroblastoma with an infusion of the patient's own T cells that have been genetically modified to express a chimeric antigen…
- Trial name
- NCT02919046
- Testing
- GD2-targeted CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 22 people
- Sponsor
- Sinobioway Cell Therapy Co., Ltd.
Advanced or Metastatic Solid Tumors
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are…
- Trial name
- NCT06781983
- Testing
- IPH4502
- Where
- 7 sites in United States, France
- Volunteers
- 145 people
- Sponsor
- Innate Pharma
Glioblastoma, Glioma
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
This open-label, multicenter, Phase I, dose-escalating study will evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of GDC-0084 in patients with progressive or recurrent high-grade glioma.
- Trial name
- NCT01547546
- Testing
- GDC-0084
- Where
- 5 sites in United States, Spain
- Volunteers
- 29 people
- Sponsor
- Genentech, Inc.
Melanoma
A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma
This is an adaptive clinical trial that includes a dose escalation phase followed by a randomized controlled Phase 3 trial. The purpose of the dose escalation phase is to establish the Phase 3 dose of indoximod in combination…
- Trial name
- NLG2107 (NCT03301636)
- Testing
- Pembrolizumab, Nivolumab, Indoximod
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- NewLink Genetics Corporation
Melanoma
A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine
The purpose of this study is to determine whether Ipilimumab will extend the life of chinese patients with Chemotherapy Naive Stage IV Melanoma more than Dacarbazine as well as to examine safety in this patient population.
- Trial name
- NCT02545075
- Testing
- Ipilimumab, Dacarbazine
- Where
- 8 sites in China
- Volunteers
- 182 people
- Sponsor
- Bristol-Myers Squibb
Malignancies, Acute Lymphoblastic Leukemia (ALL)
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary…
- Conditions
- Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma
- Trial name
- NCT03236857
- Testing
- chemotherapy, venetoclax
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 143 people
- Sponsor
- AbbVie
Melanoma
A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection
The purpose of this study is to assess the safety and tolerability of subcutaneous nivolumab vs intravenous nivolumab in participants with completely resected Stage IIIA/B/C/D or Stage IV melanoma.
- Trial name
- CheckMate-6GE (NCT05297565)
- Testing
- Nivolumab/rHuPH20, Nivolumab
- Where
- 16 sites in United States, Australia and 5 more
- Volunteers
- 14 people
- Sponsor
- Bristol-Myers Squibb
Advanced Cancer, Ovarian Cancer
3D Prediction of Patient-Specific Response
This is a prospective, non-randomized, observational registry study evaluating a patient-specific ex vivo 3D (EV3D) assay for drug response using a patient's own biopsy or resected tumor tissue for assessing tissue response to…
- Conditions
- Advanced Cancer, Ovarian Cancer, Glioblastoma Multiforme, Anaplastic Astrocytoma
- Trial name
- 3D-PREDICT (NCT03561207)
- Testing
- EV3D Assay
- Where
- 9 sites in United States
- Volunteers
- 570 people
- Sponsor
- KIYATEC
Glioblastoma Multiforme
Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme
This is an open-label, dose finding, multiple-dose study in subjects with recurring/relapsing glioblastoma multiforme. Three dose levels of MPC-6827 will be administered with carboplatin to three separate cohorts.
- Trial name
- NCT00635557
- Testing
- MPC-6827 + Carboplatin
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Myrexis Inc.
Melanoma
A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma
The purpose of this trial is to study A-dmDT390-bisFv(UCHT1) in combination with ionizing irradiation for the treatment of stage IV melanoma, a disease that is essentially incurable with median overall survival periods that range…
- Trial name
- NCT01888081
- Testing
- A-dmDT390-bisFv(UCHT1) (Resimmune®), Ionizing Radiation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Virogen Biotechnology Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.